RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Australia Channel

subscribe to Australia newsletter
Healthcare : Australia

   EMAIL   |   PRINT
AMA Urges Paroxetine Users To Consult Their Doctors

Sep 7, 2005 - 11:52:00 PM
The decision comes after a Danish study and an unpublished US study both indicate an increased risk of cardiovascular defects in children born to women taking Paroxetine.

 
[RxPG] The AMA(australia) is today alerting its members of a decision by pharmaceutical company, GlaxoSmithKline (GSK), to strengthen its warning against the use of Paroxetine for the treatment of depression in women contemplating pregnancy or in the first trimester of pregnancy.

The AMA(australia) advises patients not to worry and to seek immediate advice from their doctor.

A national response to inform patients has been prepared by the Therapeutic Goods Administration (TGA).

The decision comes after a Danish study and an unpublished US study both indicate an increased risk of cardiovascular defects in children born to women taking Paroxetine.

Paroxetine is classified as a Selective Serotonin Reuptake Inhibitors (SSRI).

The TGA advises that in Australia Paroxetine is registered under the trade names Aropax, Oxetine, Paxtine, Chem mart, GenRx and Terry White Chemists Paroxetine, Paroxetine-RL, Paroxetine-BC, Paroxetine Hexal, Espar, Loxamine, Paroxat CR, and Ausrox.

The identified problem is ventricular septal defects, which can occur also in non-SSRI users. It is a common, benign malformation that mostly resolves itself and may not even be diagnosed.

Authorities in the US and Australia stress that the problem is confined to Paroxetine and is not generalised to all SSRIs.

The GSK decision affects women on Paroxetine who are contemplating pregnancy, or who are in their first trimester of pregnancy.

It is important that women do not suddenly stop taking their Paroxetine. They must contact their doctor – GP, psychiatrist or obstetrician/gynaecologist – as soon as possible to seek advice about stopping their medication safely.



Publication: Australian Medical Association (AMA)
On the web: www.ama.com.au 

Advertise in this space for $10 per month. Contact us today.


Related Australia News
Tourist dies of mosquito-borne virus in Australia
Indian-origin couple banned from running nursing homes in Australia
Gardasil to be available in Australia by the end of 2006
Plump Australian kids urged to get out more
"Take Panic Out of Bird Flu Pandemic"
Involve GPs in Frontline Response To Possible Flu Pandemic
AMA Urges Paroxetine Users To Consult Their Doctors
World No Tobacco Day Puts Health Professionals in the Spotlight
Health System Review Must Be Based on the Medical Model, Not the Economic Model
AMA Proposes Better Health Care for Refugees

Subscribe to Australia Newsletter

Enter your email address:


 Additional information about the news article
Women interested in participating in the treatment study may contact McCrady and Epstein and their colleagues at (732)-445-0900. More information about the Rutgers Women’s Treatment Project is available at womenandalcohol.rutgers.edu.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)